MB

Check-Cap Ltd.

MBAIHealthcareNASDAQ

Diagnostics & Research

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$0
Net Income
$4.1M
+116.5% YoY
EBITDA
$4.4M
+117.5% YoY
Free Cash Flow
$846,875

Scan Results

Daily timeframe
5 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 14 MACD Positive CrossoverHistogram +0.0058, positive momentum
Jul 13 MACD Positive CrossoverHistogram +0.0075, positive momentum
About Check-Cap Ltd.

Headquartered within the healthcare sector, Check-Cap Ltd. focuses on Diagnostics & Research services and products. Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology for the detection of precancerous colorectal polyps. The $7.9M market capitalization puts MBAI squarely in micro-cap range for its industry.

Where MBAI stands vs its 150-day and 200-day moving averages

As of the July 14, 2026 close, MBAI finished 31.10% below its 150-day moving average ($1.64) and 32.34% below its 200-day moving average ($1.67). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is MBAI overbought or oversold?

At the July 14, 2026 close, MBAI's RSI(14) was 33.7, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$7.9M
P/E (TTM)1.46
EPS$0.70
Beta0.79
52W Change+34.3%
ROE416.7%
Analysis

Check-Cap Ltd. holds $219K in cash against $16K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $847K, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 416.7% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.

The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MBAI.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms
MBAI: Check-Cap Ltd. Technical Analysis (200-Day MA, RSI, MACD) | Scanance